Recombinant L. monocytogenes-based vaccines expressing tumor-associated antigens (TAAs), including endoglin (CD105) [12], human prostate-specific antigen (PSA) [13], HER-2/neu [14], and HPV16 E7 [15], have been developed for cancer immunotherapy in preclinical and clinical trials. This evidence concerns the gene ERBB2 and neoplasm.